Indaptus Therapeutics, Inc. (INDP) Current Ratio
- Current ratio · latest quarter: Value 2.34×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-03-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 2.34× | Current assets / current liabilities. $2.18M ÷ $933.00K ≈ 2.34× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 2.18M USD | Assets, Current |
| Current obligations | 933.00K USD | Liabilities, Current |
| Cash and equivalents | 1.50M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 557.37K USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | $2.18M | $933.00K | $1.50M | (m) | (m) | (m) | $557.37K | (m) | 2.34× |
| 2025-12-31 | $9.31M | $6.16M | $8.51M | (m) | (m) | (m) | $544.06K | (m) | 1.51× |
| 2025-09-30 | $6.44M | $2.23M | $5.83M | (m) | (m) | (m) | $707.42K | (m) | 2.88× |
| 2025-06-30 | $6.41M | $8.51M | $6.16M | (m) | (m) | (m) | $618.51K | (m) | 0.75× |
| 2025-03-31 | $4.96M | $2.61M | $3.89M | (m) | (m) | (m) | $1.31M | (m) | 1.90× |
| 2024-12-31 | $6.62M | $3.39M | $5.79M | (m) | (m) | (m) | $870.23K | (m) | 1.95× |
| 2024-09-30 | $7.63M | $2.23M | $7.38M | (m) | (m) | (m) | $555.95K | (m) | 3.42× |
| 2024-06-30 | $7.49M | $1.93M | $7.30M | (m) | (m) | (m) | $416.56K | (m) | 3.88× |
| 2024-03-31 | $10.29M | $1.54M | $9.74M | (m) | (m) | (m) | $405.46K | (m) | 6.70× |
| 2023-12-31 | $14.00M | $2.77M | $13.36M | (m) | (m) | (m) | $806.00K | (m) | 5.05× |
| 2023-09-30 | $16.84M | $2.37M | $15.96M | (m) | (m) | (m) | $617.27K | (m) | 7.12× |
| 2023-06-30 | $19.87M | $2.10M | $12.70M | $6.99M | (m) | (m) | $747.67K | (m) | 9.45× |
| 2023-03-31 | $22.15M | $1.82M | $6.81M | $14.88M | (m) | (m) | $382.10K | (m) | 12.15× |
| 2022-12-31 | $27.24M | $3.43M | $9.63M | $16.81M | (m) | (m) | $1.38M | (m) | 7.94× |
| 2022-09-30 | $29.59M | $2.88M | $6.72M | $21.74M | (m) | (m) | $1.25M | (m) | 10.27× |
| 2022-06-30 | $33.27M | $3.62M | $14.26M | $18.75M | (m) | (m) | $2.43M | (m) | 9.18× |
| 2022-03-31 | $36.92M | $3.68M | $33.22M | $2.96M | (m) | (m) | $2.83M | (m) | 10.03× |
| 2021-12-31 | $40.39M | $4.60M | $39.13M | (m) | (m) | (m) | $2.54M | (m) | 8.77× |
| 2021-09-30 | $43.85M | $5.78M | $41.86M | (m) | (m) | (m) | $3.34M | (m) | 7.59× |
| 2021-06-30 | $18.79M | $5.44M | $16.99M | (m) | (m) | (m) | (m) | (m) | 3.45× |
| 2020-12-31 | $1.73M | $2.02M | $1.64M | (m) | (m) | (m) | $155.96K | (m) | 0.86× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |